Gland Pharma Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Gland Pharma Receives Approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma has received approval for Zoledronic Acid Injection in the 4 mg/100 mL (0.04 mg/mL) single-dose bag format, as disclosed in a press release dated February 6, 2026. The product is a generic injectable commonly used in the treatment of osteoporosis, bone metastases, and hypercalcemia of malignancy. The approval allows the company to manufacture and market this formulation in applicable markets. No specific revenue projections, market size data, or launch timeline were provided in the filing.
The approval strengthens Gland Pharma's injectable generics portfolio and could contribute to long-term revenue growth, though no financial figures or immediate commercial impact details were disclosed.